2015
DOI: 10.1167/iovs.15-16591
|View full text |Cite
|
Sign up to set email alerts
|

Corneal Anesthesia With Site 1 Sodium Channel Blockers and Dexmedetomidine

Abstract: Coadministration of S1SCBs with dexmedetomidine provided prolonged corneal anesthesia without delaying corneal wound healing. Such formulations may be useful for the management of acute surgical and nonsurgical corneal pain.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
22
0

Year Published

2015
2015
2023
2023

Publication Types

Select...
8
1

Relationship

5
4

Authors

Journals

citations
Cited by 21 publications
(22 citation statements)
references
References 42 publications
(70 reference statements)
0
22
0
Order By: Relevance
“…DMED is known to prolong the effects of local anesthetics, both conventional [2628] and site 1 sodium channel blockers [9]. One type of potential mechanism for this prolongation is analgesic effects mediated by α 2 -adrenergic agonism or blockade of hyperpolarization-activated cation currents [29, 30].…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…DMED is known to prolong the effects of local anesthetics, both conventional [2628] and site 1 sodium channel blockers [9]. One type of potential mechanism for this prolongation is analgesic effects mediated by α 2 -adrenergic agonism or blockade of hyperpolarization-activated cation currents [29, 30].…”
Section: Discussionmentioning
confidence: 99%
“…The efficacy of TTX can be greatly enhanced by co-administration with a variety of compounds [6, 7]; the α 2 -adrenergic agonist dexmedetomidine (DMED) is one such compound [8]. Its enhancement of the activity of TTX may be due to local vasoconstriction, which would maintain a high local concentration of drug, but other mechanisms are possible [9]. Here we have hypothesized that if TTX could be released against a background of release of DMED, each quantity of released TTX would be more effective, allowing lower irradiances – releasing less TTX – to achieve a given therapeutic effect.…”
Section: Introductionmentioning
confidence: 99%
“…The intensity and duration of nerve block from any given release event could be extended by the codelivery of drugs that enhance the effectiveness of site 1 sodium-channel blockers, including amino-amide and amino-ester ("conventional") local anesthetics (6,50,53), vasoconstrictors (50,53), and dexmedetomidine (54). The basal release of TTX from the liposomes could be slowed by designing vesicles that can revert to their original state and maintain their physical integrity after irradiation, allowing further triggered events.…”
Section: J/cmmentioning
confidence: 99%
“…To further enhance the number and duration of ultrasound-triggerable nerve blocks, we co-administered dexmedetomidine-loaded liposomes (Lipo-DMED, see Figure S8 for cryo-TEM image, see Methods for synthesis) with Lipo-PPIX-TTX at a 1:2 (Lipo-DMED: Lipo-PPIX-TTX) mass ratio. Dexmedetomidine, an α 2 -adrenergic agonists, prolongs the local anesthetic effects of TTX 28 Lipo-PPIX-TTX + Lipo-DMED caused an initial nerve block of 34.5 ± 5.0 h ( Figure 5 , Table S2 ). Repeated insonation (3 W/cm 2 , 1 MHz, 10 min) after the return to ≤ 4 s latency triggered three separate consecutive nerve blocks with durations of 1.8 ± 1.2 h, 0.9 ± 0.3 h, and 0.5 ± 0.3 h respectively ( Figure 5a , Table S2 ).…”
Section: Resultsmentioning
confidence: 99%